Ann: ATH Presentation Tracking MSA Progression at Intl Symposium, page-5

I’m still hopeful the MJFF will provide some $$$ next year, but a CR will be needed at some stage for a Phase 3 trial of ATH434, it’s just a matter of timing. I expect it to be in 1H CY2025. Alterity has done 7 presentations this year by my count, this one being the 7th, so they are getting the word out. This is one area of Stamler’s performance I have been pleased with. I’m sure “professional and sophisticated investors” (i hate that term, i really do) are being sounded out now. By waiting until after the data readout in January, assuming the results are outstanding, it will give confidence to invest.